Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

FDA approves Lilly’s Reyvow for migraine
FDA approved Reyvow lasmiditan from Eli Lilly and Co. (NYSE:LLY) to treat acute migraine with or without aura. It is the first agonist of serotonin (5-HT1F) approved for the indication. Lilly regained lasmiditan in 2017 through its $960 million acquisition of CoLucid Pharmaceuticals Inc. (see "Lilly's Lasmiditan Passes Second Phase III Test").

Rubraca available on England’s Cancer Drugs Fund
U.K.’s NICE has recommended use of Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS) for women with relapsed ovarian cancer through the Cancer Development Fund.

Evotec, Celmatix partner on reproductive health candidates
Evotec SE (Xetra:EVT) has partnered with Celmatix Inc. to develop preclinical candidates for women’s reproductive health, including polycystic ovary syndrome (PCOS), endometriosis and infertility. Evotec will provide medicinal chemistry, in vitro and in vivo pharmacology and its development capabilities, while Celmatix will contribute target discovery via its multi-omics Reproductive Atlas technology. Financial terms were not disclosed.

Avacta, ADC in cancer deal
Avacta Group plc (LSE:AVCT) partnered with ADC Therapeutics S.A. to develop Affimer-drug conjugates combining Avacta’s Affimer technology with ADC’s pyrrolobenzodiazepine (PBD)-based warhead and linker technologies. ADC will cover Avacta’s costs, and Avacta is eligible for option fees, development and commercialization milestones and single-digit royalties. Financial details were not disclosed.

Neumentum in-licenses J&J pain compound
Pain company Neumentum Inc. licensed global rights to JNJ-10450232 and backup compounds from the Janssen Pharmaceutica N.V. and McNeil Consumer Pharmaceuticals Co. divisions of Johnson & Johnson (NYSE:JNJ). The oral analgesic, which has completed Phase IIa testing, is in development for moderate to moderately severe acute pain. Financial terms were not disclosed.

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE